Amneal Pharmaceuticals, Inc.(AMRX) Stock Research - Grey Stern Research
Loading...

Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis

$8.73 (1.39%)

AMRX Financial Performance


Use the table below to view Amneal Pharmaceuticals, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q1 - 2024

Metric Value Ranking among Peers
Price $8.73 -
52 Week Low $3.99 -
52 Week High $8.95 -
Market Cap $2.7 Billion 4/18
Gross Margin 36% 17/18
Profit Margin 2% 9/18
EBITDA margin 14% 9/18
Q1 - 2024 Revenue $701.8 Million 1/18
Q1 - 2024 Earnings $16.8 Million 5/18
Q1 - 2024 Free Cash Flow $0 Million 18/18
Trailing 4 Quarters Revenue $2.6 Billion 1/18
Trailing 4 Quarters Earnings -$163.8 Million 16/18
Quarterly Earnings Growth 41% 11/18
Annual Earnings Growth -792% 17/18
Quarterly Revenue Growth 17% 9/18
Annual Revenue Growth 14% 10/18
Cash On Hand $43.8 Million 13/18
Short Term Debt $272.6 Million 1/18
Long Term Debt $2.3 Billion 1/18

Amneal Pharmaceuticals, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Amneal Pharmaceuticals, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 12/18
PS 1.04 13/18
PB 0.00 16/18
PC 61.74 1/18
Liabilities to Equity 0.00 15/18
ROA -0.05 12/18
ROE 2.85 1/18
Current Ratio 0.98 15/18
Quick Ratio 0.01 17/18
Long Term Debt to Equity -39.56 18/18
Debt to Equity -44.31 18/18
Burn Rate 0.31 11/18
Cash to Cap 0.02 18/18
CCR 18/18
EV to EBITDA 54.52 4/18
EV to Revenue 2.00 13/18

Company Details

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

CEO: Mr. Chirag Patel

Website: https://www.amneal.com

Address: 400 Crossing Blvd Fl 3 Bridgewater, NEW JERSEY

Exchange: New York Stock Exchange

Industry: Drug Manufacturers—Specialty & Generic

Amneal Pharmaceuticals, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Amneal Pharmaceuticals, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Dynavax Technologies Corporation DVAX $1.7 Billion
Neurocrine Biosciences, Inc. NBIX $12.7 Billion
Ironwood Pharmaceuticals, Inc. IRWD $792.3 Million
Collegium Pharmaceutical, Inc. COLL $1.0 Billion
Eagle Pharmaceuticals, Inc. EGRX $11.7 Million
Alkermes plc ALKS $4.7 Billion
Intra-Cellular Therapies, Inc. ITCI $9.7 Billion
ANI Pharmaceuticals, Inc. ANIP $1.3 Billion
Amphastar Pharmaceuticals, Inc. AMPH $2.4 Billion
Phibro Animal Health Corporation PAHC $966.0 Million
AcelRx Pharmaceuticals, Inc. ACRX $14.6 Million
Agile Therapeutics, Inc. AGRX $10.4 Million
Deciphera Pharmaceuticals, Inc. DCPH $2.2 Billion
Evolus, Inc. EOLS $863.1 Million
Assertio Holdings, Inc. ASRT $81.0 Million
Silver Spike Investment Corp. SSIC $66.7 Million
Procaps Group S.A. PROC $174.6 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
AMRX Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 701.8 Million $16.8 Million
Q1 2024 $ 659.2 Million -$91.6 Million
Q4 2023 $ 617.0 Million -$98.6 Million
Q3 2023 $ 620.0 Million $9.7 Million
Q2 2023 $ 599.0 Million $11.9 Million
Q1 2023 $ 557.5 Million -$10.1 Million
Q4 2022 $ 609.8 Million -$5.9 Million
Q3 2022 $ 545.6 Million -$2.7 Million

View All

AMRX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $43.8 Million $3.5 Billion $2.5 Billion -$4.0 Million
Q1 2024 $46.5 Million $3.5 Billion $2.7 Billion -$16.6 Million
Q4 2023 $91.5 Million $3.5 Billion $2.5 Billion $61.3 Million
Q3 2023 $86.9 Million $3.7 Billion $2.8 Billion $191.4 Million
Q2 2023 $109.3 Million $3.7 Billion $2.9 Billion $150.8 Million
Q1 2023 $144.7 Million $3.6 Billion $2.9 Billion $134.7 Million
Q4 2022 $26.0 Million $3.8 Billion $2.8 Billion $184.0 Million
Q3 2022 $87.3 Million $3.9 Billion $2.8 Billion $194.3 Million

View All

AMRX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q1 2024 -$24.2 Million -$19.8 Million -$47.5 Million
Q4 2023 -$20.6 Million $0 -$20.6 Million
Q3 2023 $67.9 Million -$13.5 Million -$19.0 Million
Q2 2023 -$23.6 Million -$12.3 Million -$36.5 Million
Q1 2023 $128.0 Million -$11.7 Million $115.8 Million
Q4 2022 -$34.8 Million -$11.5 Million -$60.7 Million
Q3 2022 $44.2 Million -$49.3 Million -$2.3 Million
Q2 2022 -$142.6 Million -$17.1 Million -$118.4 Million

View All